Anteris Technologies Global (NASDAQ:AVR) Shares Up 12.6% – Should You Buy?

Anteris Technologies Global Corp. (NASDAQ:AVR) shares shot up 12.6% during trading on Thursday . The stock traded as high as $9.71 and last traded at $10.0750. 176,960 shares were traded during mid-day trading, a decline of 84% from the average session volume of 1,133,399 shares. The stock had previously closed at $8.95.

Analyst Upgrades and Downgrades

Several research analysts recently weighed in on the stock. Wall Street Zen upgraded shares of Anteris Technologies Global from a “sell” rating to a “hold” rating in a research report on Saturday, May 16th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Anteris Technologies Global in a research note on Friday, May 29th. Cantor Fitzgerald restated an “overweight” rating and set a $15.00 price objective on shares of Anteris Technologies Global in a research note on Friday, March 27th. Barclays increased their price objective on shares of Anteris Technologies Global from $17.00 to $18.00 and gave the stock an “overweight” rating in a research note on Friday, May 15th. Finally, Wells Fargo & Company assumed coverage on shares of Anteris Technologies Global in a research note on Wednesday, March 11th. They issued an “overweight” rating and a $16.00 target price for the company. Four research analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the stock. According to data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $16.00.

Anteris Technologies Global Price Performance

The business’s 50-day moving average price is $6.66 and its two-hundred day moving average price is $5.79. The company has a market capitalization of $937.87 million, a price-to-earnings ratio of -4.37 and a beta of 1.78.

Anteris Technologies Global (NASDAQ:AVR) last released its quarterly earnings results on Tuesday, May 12th. The company reported ($0.28) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.27) by ($0.01). Anteris Technologies Global had a negative net margin of 5,148.78% and a negative return on equity of 124.76%. The business had revenue of $0.49 million during the quarter, compared to analyst estimates of $0.77 million. During the same quarter in the previous year, the firm posted ($0.61) earnings per share. As a group, research analysts predict that Anteris Technologies Global Corp. will post -1.14 EPS for the current year.

Institutional Inflows and Outflows

A number of hedge funds have recently added to or reduced their stakes in the company. L1 Capital Pty Ltd grew its stake in shares of Anteris Technologies Global by 143.2% during the third quarter. L1 Capital Pty Ltd now owns 6,838,136 shares of the company’s stock worth $30,772,000 after buying an additional 4,026,136 shares during the last quarter. ADAR1 Capital Management LLC lifted its position in Anteris Technologies Global by 205.9% in the 1st quarter. ADAR1 Capital Management LLC now owns 3,789,132 shares of the company’s stock valued at $21,030,000 after acquiring an additional 2,550,355 shares in the last quarter. Perceptive Advisors LLC lifted its position in Anteris Technologies Global by 104.4% in the 1st quarter. Perceptive Advisors LLC now owns 3,425,476 shares of the company’s stock valued at $19,011,000 after acquiring an additional 1,750,000 shares in the last quarter. Nantahala Capital Management LLC lifted its position in Anteris Technologies Global by 31.9% in the 4th quarter. Nantahala Capital Management LLC now owns 2,530,910 shares of the company’s stock valued at $12,629,000 after acquiring an additional 612,244 shares in the last quarter. Finally, JPMorgan Chase & Co. lifted its position in Anteris Technologies Global by 32.7% in the 3rd quarter. JPMorgan Chase & Co. now owns 1,417,627 shares of the company’s stock valued at $6,379,000 after acquiring an additional 349,299 shares in the last quarter.

About Anteris Technologies Global

Anteris Technologies Global Corp. engages in the development and commercialization of medical devices for heart diseases. The company was founded in 1999 and is headquartered in Eagan, MN.